<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1707">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569383</url>
  </required_header>
  <id_info>
    <org_study_id>UKE-DZIF-SARS-CoV-2</org_study_id>
    <nct_id>NCT04569383</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19</brief_title>
  <official_title>An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Center for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase I first-in-human clinical trial, healthy volunteers in two different dose
      cohorts will be vaccinated twice with the candidate vaccine MVA-SARS-2-S.

      The aim of the study is to assess the safety and tolerability of the candidate vaccine and to
      characterize its immunogenicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2
      spike protein (S). A total of 30 participants will receive the following vaccine regime:

      15 participants will receive 10^7 infectious units (IU) of MVA-SARS-2-S on days 0 and 28.

      15 participants will receive 10^8 IU of MVA-SARS-2-S on days 0 and 28. Safety and
      immunogenicity data will be collected throughout the study, which concludes at day 168.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol</measure>
    <time_frame>during the entire study (up to 6 months)</time_frame>
    <description>Safety and reactogenicity will be assessed by observation, questionaire and diary. Occurence of Serious Adverse Events (SAE) will be collected throughout the entire study duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity. Number of participants who seroconverted</measure>
    <time_frame>during the entire study (up to 6 months)</time_frame>
    <description>Magnitude of SARS-CoV2-specific antibody responses (ELISA and neutralization assays) monitored in an approved laboratory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>1x10E7 IU (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1x10E7 IU MVA-SARS-2-S</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1x10E8 IU (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1x10E8 MVA-SARS-2-S</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-SARS-2-S vaccinations (days 0 &amp; 28)</intervention_name>
    <description>Vaccination with MVA-SARS-2-S in two escalating dose regimens</description>
    <arm_group_label>1x10E7 IU (low dose)</arm_group_label>
    <arm_group_label>1x10E8 IU (high dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Healthy male and female adults aged 18-55 years

          -  No clinically significant health problems as determined during medical history and
             physical examination at screening visit

          -  Body mass index 18.5 - 30.0 kg/m2 and weight &gt; 50 kg at screening

          -  Adults male or non-pregnant, non-lactating female with negative pregnancy test

          -  Males and females who agree to comply with the applicable contraceptive requirements
             of the protocol

        Exclusion Criteria:

          -  Prior exposure to SARS-CoV-2

          -  Receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live
             vaccines) to 6 weeks after each trial vaccination

          -  Previous rMVA immunization

          -  Known allergy to the components of the SARS-CoV-2 vaccine product

          -  Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by
             any component of the trial vaccine

          -  Evidence in the subject's medical history or in the medical examination that might
             influence either the safety of the subject or the absorption, distribution, metabolism
             or excretion of the investigational product

          -  Clinically relevant findings in ECG

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic
             therapy in the previous 5 years, and/or diabetes

          -  Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding
             a single febrile seizure as a child
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marylyn M Addo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marylyn M Addo, MD</last_name>
    <phone>+49 407410</phone>
    <phone_ext>0</phone_ext>
    <email>m.addo@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>CTC North GmbH &amp; Co KG at the University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MVA</keyword>
  <keyword>vaccine</keyword>
  <keyword>SARS-CoV-2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

